Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 11/20 | 0.48 |
| ▸ | RARA | P10276 | 10/20 | 0.48 |
| ▸ | RARG | P13631 | 10/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | ALKBH3 | Q96Q83 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.33 |
| ▸ | TDP2 | O95551 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4500355 | 0.84 | RARA (0.50) | RARBRARARARGCYP3A4BACE1 | |
| SCHEMBL4491751 | 0.77 | RARB (0.48) | RARBRARARARGRXRANR2E1 | |
| SCHEMBL4511245 | 0.76 | RARA (0.58) | RARBRARARARG | |
| SCHEMBL5047691 | 0.74 | RARG (0.57) | RARBRARARARG | |
| SCHEMBL4506863 | 0.74 | RARB (0.48) | RARBRARARARGRXRANR2E1 | |
| SCHEMBL4509207 | 0.72 | RARB (0.44) | RARBRARARARG | |
| SCHEMBL5162872 | 0.72 | RARB (0.47) | RARBRARARARGRXRANR2E1 | |
| SCHEMBL8710667 | 0.70 | RARA (0.53) | RARBRARARARGRXRANR2E1 | |
| SCHEMBL6247945 | 0.69 | RARB (0.47) | RARBRARARARGRXRANR2E1 | |
| SCHEMBL8709506 | 0.69 | RARB (0.80) | RARBRARARARGRXRANR2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7592478-B2 | Ligand antagonists of RAR receptors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-09-22 | — | — | US | disclosed |
| US-20080213347-A1 | Novel ligand antagonists of RAR receptors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. | 2008-09-04 | — | — | US | disclosed |
| US-7348449-B2 | Ligand antagonists of RAR receptors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-03-25 | — | — | US | disclosed |
| EP-1565433-B1 | NOVEL LIGANDS THAT ARE ANTAGONISTS OF RAR RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RES & DEV (FR) | 2007-03-14 | — | — | EP | disclosed |
| US-20050234131-A1 | Novel ligand antagonists of RAR receptors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234131-A1 | Novel ligand antagonists of RAR receptors and pharmaceutical/cosmetic applications thereof | RARB, RARG, RARA | RARB 1/4885RARA 3/4885RARG 2/4885 |
| US-20080213347-A1 | Novel ligand antagonists of RAR receptors and pharmaceutical/cosmetic applications thereof | RARB, RARG, RARA | RARB 1/4885RARA 3/4885RARG 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.